原発性進行性多発性硬化症（PPMS）治療の世界市場レポート2025年

原発性進行性多発性硬化症（PPMS）治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.5%で19億2,000万米ドルに成長します。この予想される成長の原動力は、新規PPMS治療法を模索する臨床試験の増加、診断法の進歩、精密医療や標的医療への嗜好の高まり、ヘルスケアインフラの改善、製薬企業間の連携やパートナーシップの強化などです。予測期間中に予想される主な動向としては、PPMSの進行阻止を目的とした疾患修飾療法の革新、個別化治療のためのバイオマーカー研究の応用、MRIなどの画像技術の強化、神経保護・再髄鞘化薬の開発における進歩、より正確な治療計画のための遺伝子・分子プロファイリングの画期的進歩などが挙げられます。

効果的な治療に対する需要の高まりが、今後の原発性進行性多発性硬化症（PPMS）治療市場の成長を促進すると予想されます。効果的な治療とは、症状を軽減し、患者の転帰を改善し、疾患や状態を治癒させる医療介入です。この需要は主に、患者の転帰と生活の質を改善するために長期的な管理と高度な治療介入を必要とする、慢性的で複雑な健康状態の有病率の上昇によってもたらされます。これらの治療は、炎症を標的とし神経機能を維持することで原発性進行性多発性硬化症（PPMS）の進行を遅らせ、それによって長期的なQOLを改善し、障害の蓄積を抑え、患者がより自立して安定した日常生活を営む能力を高めるのに役立ちます。例えば、遺伝子・細胞治療の米国団体である米国遺伝子・細胞治療学会によると、2024年1月、第III相臨床試験中の遺伝子治療薬の数は、2023年には33試験に達し、2022年に比べて10％増加し、2022年第3四半期以来の四半期ごとの増加となりました。したがって、効果的な治療に対する需要の高まりが原発性進行性多発性硬化症（PPMS）治療市場の成長を牽引しています。

原発性進行性多発性硬化症（PPMS）治療市場で事業を展開する主要企業は、多発性硬化症の治療を強化するために、モノクローナル抗体医薬などの革新的な製剤の開発に注力しています。モノクローナル抗体医薬品は、炎症や神経系への損傷を引き起こす特定の免疫細胞やタンパク質を標的とすることで、多発性硬化症の治療に役立ち、疾患活動性を低下させ、症状の進行を遅らせる。例えば、2024年2月、インドの製薬会社ロシュ・ファーマ・インディアは、インドで多発性硬化症（MS）の治療薬としてモノクローナル抗体薬オクレブス（オクレリズマブ）を発売しました。オクレブスは、再発寛解型多発性硬化症（RRMS）と原発性進行性多発性硬化症（PPMS）の両方に対して、インドで初めて、そして唯一承認された疾患修飾療法（DMT）であることで注目されています。この薬剤は、MSで見られる異常な免疫反応に関与する免疫細胞の一種であるCD20陽性B細胞を標的とすることで効果を発揮します。年2回、わずか2時間の点滴静注で投与されるため、患者にとってより便利で効果的な治療選択肢となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の原発性進行性多発性硬化症（PPMS）治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の原発性進行性多発性硬化症（PPMS）治療市場：成長率分析
• 世界の原発性進行性多発性硬化症（PPMS）治療市場の実績：規模と成長, 2019-2024
• 世界の原発性進行性多発性硬化症（PPMS）治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の原発性進行性多発性硬化症（PPMS）治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の原発性進行性多発性硬化症（PPMS）治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 免疫抑制剤
• コルチコステロイド
• その他の薬物の種類
• 世界の原発性進行性多発性硬化症（PPMS）治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• その他の投与経路
• 世界の原発性進行性多発性硬化症（PPMS）治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の原発性進行性多発性硬化症（PPMS）治療市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オクレリズマブ
• リツキシマブ
• オファツムマブ
• ウブリツキシマブ
• 世界の原発性進行性多発性硬化症（PPMS）治療市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトトレキサート
• アザチオプリン
• ミコフェノール酸モフェチル
• シクロホスファミド
• 世界の原発性進行性多発性硬化症（PPMS）治療市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メチルプレドニゾロン
• プレドニゾン
• デキサメタゾン
• ヒドロコルチゾン
• 世界の原発性進行性多発性硬化症（PPMS）治療市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビオチン
• イブジラスト
• ラキニモド
• イデベノン

第7章 地域別・国別分析

• 世界の原発性進行性多発性硬化症（PPMS）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の原発性進行性多発性硬化症（PPMS）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 原発性進行性多発性硬化症（PPMS）治療市場：競合情勢
• 原発性進行性多発性硬化症（PPMS）治療市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer HealthCare Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Acorda Therapeutics Inc.
• Apitope International N.V.
• Atara Biotherapeutics Inc.
• Kyverna Therapeutics Inc.
• Clene Inc.
• Mapi Pharma Ltd.
• Abata Therapeutics Inc.
• MediciNova Inc.
• MedDay Pharmaceuticals SAS
• AB Science S.A.
• Immunic AG
• Brainstorm Cell Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 原発性進行性多発性硬化症（PPMS）治療市場2029：新たな機会を提供する国
• 原発性進行性多発性硬化症（PPMS）治療市場2029：新たな機会を提供するセグメント
• 原発性進行性多発性硬化症（PPMS）治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Primary progressive multiple sclerosis (PPMS) treatment encompasses medical and therapeutic strategies designed to manage and slow the progression of PPMS-a form of multiple sclerosis marked by a continuous decline in neurological function from the onset, without distinct relapses or remissions. These interventions aim to reduce disease activity, ease symptoms, preserve mobility, and enhance patients' quality of life.

The primary drug categories utilized in the management of primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and various other drug types. Monoclonal antibodies (mAbs) are synthetically engineered proteins that specifically bind to antigens on affected cells, serving diagnostic or therapeutic functions. These medications are delivered through different routes such as oral, intravenous, and others, and are made available via hospital pharmacies, retail pharmacies, online pharmacies, and additional distribution channels.

The primary progressive multiple sclerosis (PPMS) treatment market size has grown rapidly in recent years. It will grow from $1.02 billion in 2024 to $1.16 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. Growth during the historic period was supported by the increasing incidence of PPMS among older adults, enhanced awareness and knowledge of the condition among patients and medical professionals, higher R&D investments targeting PPMS therapies, greater use of disease-modifying treatments, and amplified governmental support and funding for emerging treatment options.

The primary progressive multiple sclerosis (PPMS) treatment market size is expected to see rapid growth in the next few years. It will grow to $1.92 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. This anticipated growth will be driven by the rising number of clinical trials exploring novel PPMS therapies, progress in diagnostic methods, a growing preference for precision and targeted medicine, improvements in healthcare infrastructure, and stronger collaboration and partnerships between pharmaceutical firms. Key trends expected during the forecast period include innovation in disease-modifying therapies aimed at halting PPMS progression, the application of biomarker studies for personalized treatment, enhanced imaging technologies such as MRI, advancements in neuroprotection and remyelination drug development, and breakthroughs in genetic and molecular patient profiling for more accurate treatment planning.

The growing demand for effective treatments is expected to propel the growth of the primary progressive multiple sclerosis (PPMS) treatment market going forward. Effective treatments are medical interventions that reduce symptoms, improve patient outcomes, or cure a disease or condition. This demand is primarily driven by the rising prevalence of chronic and complex health conditions, which require long-term management and advanced therapeutic interventions to improve patient outcomes and quality of life. These treatments help slow the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thereby improving long-term quality of life, reducing disability accumulation, and enhancing patients' ability to manage daily activities with greater independence and stability. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, an increase of 10% compared to 2022, representing the first quarterly increase since Q3 2022. Therefore, the growing demand for effective treatments drives the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on developing innovative formulations such as monoclonal antibody drugs to enhance the treatment of multiple sclerosis. A monoclonal antibody drug helps in multiple sclerosis by targeting specific immune cells or proteins that cause inflammation and damage to the nervous system, reducing disease activity and slowing the progression of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, to treat multiple sclerosis (MS) in India. Ocrevus is notable for being the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug works by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response seen in MS. It is administered as a twice-yearly intravenous infusion for only two hours, offering patients a more convenient and effective treatment option.

In March 2024, Viatris Inc., a US-based healthcare company focused on providing access to medicines, partnered with Mapi Pharma Ltd. to advance the development and commercialization of GA Depot 40 mg for multiple sclerosis treatment. Through this partnership, Viatris supports the regulatory and commercial pathway for GA Depot, a long-acting injectable therapy to improve treatment adherence and address unmet medical needs in managing multiple sclerosis. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot technologies and sustained-release formulations for central nervous system disorders, including multiple sclerosis.

Major players in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, Brainstorm Cell Therapeutics Inc.

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary progressive multiple sclerosis (PPMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary progressive multiple sclerosis (PPMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary progressive multiple sclerosis (ppms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary progressive multiple sclerosis (ppms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary progressive multiple sclerosis (ppms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Monoclonal Antibodies; Immunosuppressants; Corticosteroids; Other Drug Types
• 2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Monoclonal Antibodies: Ocrelizumab; Rituximab; Ofatumumab; Ublituximab
• 2) By Immunosuppressants: Methotrexate; Azathioprine; Mycophenolate Mofetil; Cyclophosphamide
• 3) By Corticosteroids: Methylprednisolone; Prednisone; Dexamethasone; Hydrocortisone
• 4) By Other Drug Types: Biotin; Ibudilast; Laquinimod; Idebenone
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bayer HealthCare Pharmaceuticals Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Characteristics

3. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends And Strategies

4. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Growth Rate Analysis
• 5.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Total Addressable Market (TAM)

6. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segmentation

• 6.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Immunosuppressants
• Corticosteroids
• Other Drug Types
• 6.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Other Route Of Administrations
• 6.3. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ocrelizumab
• Rituximab
• Ofatumumab
• Ublituximab
• 6.5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methotrexate
• Azathioprine
• Mycophenolate Mofetil
• Cyclophosphamide
• 6.6. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methylprednisolone
• Prednisone
• Dexamethasone
• Hydrocortisone
• 6.7. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biotin
• Ibudilast
• Laquinimod
• Idebenone

7. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional And Country Analysis

• 7.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 8.1. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 9.1. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 9.2. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 10.1. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 11.1. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 11.2. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 12.1. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 13.1. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 14.1. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 14.2. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 15.1. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 15.2. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 16.1. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 17.1. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 18.1. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 19.1. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 20.1. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 21.1. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 21.2. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 22.1. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 23.1. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 23.2. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 24.1. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 24.2. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 25.1. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 25.2. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 26.1. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 26.2. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 27.1. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 28.1. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 28.2. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 29.1. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• 29.2. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape
• 30.2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer HealthCare Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Biogen Inc.
• 31.4. Acorda Therapeutics Inc.
• 31.5. Apitope International N.V.
• 31.6. Atara Biotherapeutics Inc.
• 31.7. Kyverna Therapeutics Inc.
• 31.8. Clene Inc.
• 31.9. Mapi Pharma Ltd.
• 31.10. Abata Therapeutics Inc.
• 31.11. MediciNova Inc.
• 31.12. MedDay Pharmaceuticals SAS
• 31.13. AB Science S.A.
• 31.14. Immunic AG
• 31.15. Brainstorm Cell Therapeutics Inc.

32. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

34. Recent Developments In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

35. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer